Armstrong Advisory Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.1K Hold
300
– – ﹤0.01% 493
2026
Q2
$23.5K Hold
300
– – ﹤0.01% 564
2026
Q1
$19.4K Hold
300
– – ﹤0.01% 573
2025
Q4
$20.2K Hold
300
– – ﹤0.01% 559
2025
Q3
$22K Hold
300
– – ﹤0.01% 541
2025
Q2
$15.6K Buy
300
+200
+200% +$11.4K ﹤0.01% 580
2025
Q1
$4.78K Hold
100
– – ﹤0.01% 700
2024
Q4
$4.78K Hold
100
– – ﹤0.01% 700
2024
Q3
$5.72K Buy
+100
New +$5.73K ﹤0.01% 650

Other funds holding HALO

Armstrong Advisory Group's HALO Position: Q3 2026 in Review

Armstrong Advisory Group held its Halozyme (HALO) position steady in Q3 2026 at 300 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Armstrong Advisory Group first reported a position in HALO in Q3 2024 and has held it in 9 quarters since. 172 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Armstrong Advisory Group held 300 shares of Halozyme worth $33.1K as of Q3 2026.
  • Armstrong Advisory Group left its Halozyme share count unchanged in Q3 2026.
  • Halozyme made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #493 holding.
  • Armstrong Advisory Group first reported a position in Halozyme in Q3 2024 and has held it in 9 quarters since.
  • 172 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.